Blueprint Medicines Co. (NASDAQ:BPMC) Insider Sells $7,713,602.46 in Stock

Blueprint Medicines Co. (NASDAQ:BPMC) insider Debra Durso-Bumpus sold 74,034 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $104.19, for a total value of $7,713,602.46. Following the transaction, the insider now owns 43,763 shares of the company’s stock, valued at $4,559,666.97. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Blueprint Medicines Stock Up 4.4 %

Shares of NASDAQ BPMC opened at $108.52 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 3.76 and a quick ratio of 3.61. The company has a 50-day moving average price of $102.86 and a 200-day moving average price of $92.45. The stock has a market capitalization of $6.80 billion, a P/E ratio of -22.56 and a beta of 0.70. Blueprint Medicines Co. has a 1 year low of $43.89 and a 1 year high of $111.02.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.64) by $0.32. Blueprint Medicines had a negative return on equity of 193.48% and a negative net margin of 102.15%. The firm had revenue of $96.12 million during the quarter, compared to the consensus estimate of $82.58 million. On average, equities research analysts forecast that Blueprint Medicines Co. will post -5.15 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have issued reports on BPMC shares. Leerink Partnrs upgraded shares of Blueprint Medicines from an “underperform” rating to a “market perform” rating in a report on Monday, May 6th. Stephens initiated coverage on shares of Blueprint Medicines in a research note on Tuesday, May 14th. They set an “overweight” rating and a $140.00 target price for the company. Citigroup increased their price target on Blueprint Medicines from $65.00 to $76.00 and gave the stock a “sell” rating in a report on Friday, May 3rd. The Goldman Sachs Group boosted their price objective on Blueprint Medicines from $121.00 to $168.00 and gave the company a “buy” rating in a research note on Monday, May 6th. Finally, SVB Leerink upgraded Blueprint Medicines from an “underperform” rating to a “market perform” rating and upped their target price for the company from $50.00 to $97.00 in a research report on Monday, May 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Blueprint Medicines presently has an average rating of “Moderate Buy” and an average price target of $108.00.

Hedge Funds Weigh In On Blueprint Medicines

Large investors have recently bought and sold shares of the stock. Readystate Asset Management LP purchased a new stake in shares of Blueprint Medicines in the fourth quarter valued at about $3,692,000. Vanguard Group Inc. lifted its position in shares of Blueprint Medicines by 2.5% during the 4th quarter. Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock worth $564,045,000 after buying an additional 147,827 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Blueprint Medicines by 5.2% in the 3rd quarter. American Century Companies Inc. now owns 670,972 shares of the biotechnology company’s stock worth $33,696,000 after buying an additional 33,243 shares during the last quarter. Axiom Investors LLC DE purchased a new position in shares of Blueprint Medicines in the 4th quarter worth approximately $2,212,000. Finally, Diversified Trust Co grew its holdings in shares of Blueprint Medicines by 2.9% in the third quarter. Diversified Trust Co now owns 11,219 shares of the biotechnology company’s stock valued at $563,000 after acquiring an additional 318 shares in the last quarter.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.